We are building our alliance of empowered young ambassadors, and expect more than 200 youth at Lorenzo’s Youth Summit 2024. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
32,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
We are building our alliance of empowered young ambassadors, and expect more than 200 youth at Lorenzo’s Youth Summit 2024. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Leveraging real-world data to better understand health care utilization patterns prior to and after incident AD diagnosis may help inform the clinical management of the disease. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MemoryCare, in its 13th year of operation in Asheville, NC, is an independent, non-profit organization dedicated to providing medical care to older adults with cognitive impairment inclusive of a case management component that provides support and education to their families and caregivers. 1 key finding →
Participants: 980 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Subcortical vascular mild cognitive impairment (svMCI) is known to be a prodromal stage of subcortical vascular dementia (SVaD) (1-3) who may also developed to mixed Alzheimer's disease (AD) (4). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among all Central Appalachian counties, 52%‐97% had broadband access throughout the study period (Figures 1‐2). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall, the pathway to diagnosis (i.e., time from signs/symptoms recognition to diagnosis) ranged from 2 to 15 years. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Overall health is significantly impacted by where one lives. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As of April 3, 2025, 944 HCPs (neurologists 14%, geriatricians 5%, primary care providers 25%) and 2,269 P/Cs engaged with the contents. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There are many types of Dementia‐Friendly Communities (DFCs), and communities define and implement them in different ways. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Medication-related health problems in the Korean elderly have been increasing very rapidly in Korea with the population of the aged increased. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Empowering family caregivers of patients with ADOD in a personalized DCEP provides durable reductions in patient hospitalizations and medical costs. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Real-world, administrative claims data is uniquely suited to help characterize the journey of Alzheimer's disease (AD) patients from the onset of disease symptoms through diagnosis and beyond. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Geographic variation in occurrence of dementia within the US has received little attention despite its importance for generation of new etiologic hypotheses and health services research. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The wave of ‘silver tsunami’ sweeping over the developed world means that the number of dementia patients expected to double to 75.6 million by 2030. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease and related dementias are known to affect both the patient and the family caregiver. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated